Association of D4-GDI expression with breast cancer progression

Cancer Biomarkers

Volumn 10, Issue 3-4, 2011, Pages 163-173

  Rosado, Leslie A Rivera ^a   Rodriguez Canales, Jaime ^b   Zhang, Baolin ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

breast cancer; D4 GDI; immunohistochemistry; progression

Indexed keywords

D4 GDI PROTEIN; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CELL; BREAST DUCT; BREAST HYPERPLASIA; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MYOEPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; NEOPLASM STAGING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862868281     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0240     Document Type: Article

References (46)

1. S. Aznar, P. Fernandez-Valeron, C. Espina and J.C. Lacal, Rho GTPases: potential candidates for anticancer therapy, Cancer Lett 206 (2004), 181-191. (Pubitemid 38317288)
2. M.W. Beckmann, D. Niederacher, H.G. Schnurch, B.A. Gusterson and H.G. Bender, Multistep carcinogenesis of breast cancer and tumour heterogeneity, J MolMed (Berl) 75 (1997), 429-439. (Pubitemid 27297013)
3. A. Bombonati and D.C. Sgroi, The molecular pathology of breast cancer progression, J Pathol 223 (2011), 307-317.
4. J.D. Brenton, L.A. Carey, A.A. Ahmed and C. Caldas, Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23 (2005), 7350-7360. (Pubitemid 46202348)
5. H.J. Cho, K.E. Baek, S.M. Park, I.K. Kim, Y.L. Choi, H.J. Cho, I.K. Nam, E.M. Hwang, J.Y. Park, J.Y. Han, S.S. Kang, D.C. Kim,W.S. Lee, M.N. Lee, G.T. Oh, J.W. Kim, C.W. Lee and J. Yoo, RhoGDI2 Expression Is Associated with Tumor Growth andMalignant Progression of Gastric Cancer, Clinical Cancer Research 15 (2009), 2612-2619.
6. R. Dent, M. Trudeau, K.I. Pritchard, W.M. Hanna, H.K. Kahn, C.A. Sawka, L.A. Lickley, E. Rawlinson, P. Sun and S.A. Narod, Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res 13 (2007), 4429-4434. (Pubitemid 47219710)
7. F. Essmann, T. Wieder, A. Otto, E.C. Müller, B. Dórken and P.T. Daniel, GDP dissociation inhibitor D4-GDI (Rho-GDI 2), but not the homologous rho-GDI 1, is cleaved by caspase-3 during drug-induced apoptosis, Biochemical Journal 346 (2000), 777-783. (Pubitemid 30171040)
8. G. Fritz, I. Just and B. Kaina, Rho GTPases are over-expressed in human tumors, Int J Cancer 81 (1999), 682-687. (Pubitemid 29214373)
9. A. Fujita, A. Shida, S. Fujioka, H. Kurihara, T. Okamoto and K. Yanaga, Clinical significance of Rho GDP dissociation inhibitor 2 in colorectal carcinoma, Int J Clin Oncol (2011).
10. A.F. Gazdar, V. Kurvari, A. Virmani, L. Gollahon, M. Sakaguchi, M. Westerfield, D. Kodagoda, V. Stasny, H.T. Cunningham, Wistuba, II, G. Tomlinson, V. Tonk, R. Ashfaq, A.M. Leitch, J.D. Minna and J.W. Shay, Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer, Int J Cancer 78 (1998), 766-774. (Pubitemid 28530401)
11. J.J. Gildea, M.J. Seraj, G. Oxford,M.A.Harding, G.M. Hampton, C.A. Moskaluk, H.F. Frierson, M.R. Conaway and D. Theodorescu, RhoGDI2 is an invasion andmetastasis suppressor gene in human cancer, Cancer Res 62 (2002), 6418-6423. (Pubitemid 35364098)
12. L.D. Hu, H.F. Zou, S.X. Zhan and K.M. Cao, Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis, Oncol Rep 17 (2007), 1383-1389.
13. W.G. Jiang, G. Watkins, J. Lane, G.H. Cunnick, A. Douglas-Jones, K. Mokbel and R.E. Mansel, Prognostic Value of Rho GTPases and Rho Guanine Nucleotide Dissociation Inhibitors in Human Breast Cancers, Clinical Cancer Research 9 (2003), 6432-6440. (Pubitemid 38031830)
14. J. Kao, K. Salari, M. Bocanegra, Y.L. Choi, L. Girard, J. Gandhi, K.A. Kwei, T. Hernandez-Boussard, P. Wang, A.F. Gazdar, J.D. Minna and J.R. Pollack, Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery, PLoS One 4 (2009), e6146.
15. R. Karlsson, E.D. Pedersen, Z. Wang and C. Brakebusch, Rho GTPase function in tumorigenesis, Biochim Biophys Acta 1796 (2009), 91-98.
16. R.J. Krieser and A. Eastman, Cleavage and nuclear translocation of the caspase 3 substrate Rho GDP-dissociation inhibitor, D4-GDI, during apoptosis, Cell Death Differ 6 (1999), 412-419. (Pubitemid 29245955)
17. N.B. Kuemmerle, E. Rysman, P.S. Lombardo, A.J. Flanagan, B.C. Lipe, W.A. Wells, J.R. Pettus, H.M. Froehlich, V.A. Memoli, P.M. Morganelli, J.V. Swinnen, L.A. Timmerman, L. Chaychi, C.J. Fricano, B.L. Eisenberg, W.B. Coleman and W.B. Kinlaw, Lipoprotein lipase links dietary fat to solid tumor cell proliferation, Mol Cancer Ther 10 (2011), 427-436.
18. S.R. Lakhani, The transition from hyperplasia to invasive carcinoma of the breast, J Pathol 187 (1999), 272-278. (Pubitemid 29064150)
19. J.M. Lelias, C.N. Adra, G.M. Wulf, J.C. Guillemot, M. Khagad, D. Caput, and B. Lim, cDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins, Proc Natl Acad Sci U S A 90 (1993), 1479- 1483.
20. X. Li, J. Wang, X. Zhang, Y. Zeng, L. Liang and Y. Ding, Overexpression of RhoGDI2 Correlates with Tumor Progression and Poor Prognosis in Colorectal Carcinoma, Ann Surg Oncol (2011).
21. E. Lim, F. Vaillant, D. Wu, N.C. Forrest, B. Pal, A.H. Hart, M.L. Asselin-Labat, D.E. Gyorki, T. Ward, A. Partanen, F. Feleppa, L.I. Huschtscha, H.J. Thorne, S.B. Fox, M. Yan, J.D. French, M.A. Brown, G.K. Smyth, J.E. Visvader and G.J. Lindeman, Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers, Nat Med 15 (2009), 907-913.
22. F. Liu and B.Wu, Multi-group cancer outlier differential gene expression detection, Comput Biol Chem 31 (2007), 65-71. (Pubitemid 46528862)
23. A.J. Minn, G.P. Gupta, P.M. Siegel, P.D. Bos, W. Shu, D.D. Giri, A. Viale, A.B. Olshen, W.L. Gerald and J. Massague, Genes that mediate breast cancer metastasis to lung, Nature 436 (2005), 518-524. (Pubitemid 41112921)
24. K. Moissoglu, K.S. McRoberts, J.A. Meier, D. Theodorescu and M.A. Schwartz, Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases, Cancer Res 69 (2009), 2838-2844.
25. H.G. Moon, S.H. Jeong, Y.T. Ju, C.Y. Jeong, J.S. Lee, Y.J. Lee, S.C. Hong, S.K. Choi, W.S. Ha, S.T. Park and E.J. Jung, Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications, Cancer Res Treat 42 (2010), 151-156.
26. R.M. Neve, K. Chin, J. Fridlyand, J. Yeh, F.L. Baehner, T. Fevr, L. Clark, N. Bayani, J.P. Coppe, F. Tong, T. Speed, P.T. Spellman, S. DeVries, A. Lapuk, N.J. Wang, W.L. Kuo, J.L. Stilwell, D. Pinkel, D.G. Albertson, F.M. Waldman, F. McCormick, R.B. Dickson, M.D. Johnson, M. Lippman, S. Ethier, A. Gazdar and J.W. Gray, A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes, Cancer Cell 10 (2006), 515-527. (Pubitemid 44854747)
27. H. Niu, H. Li, C. Xu and P. He, Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis, Oncol Rep 24 (2010), 465-471.
28. T. Ota, M. Maeda, S. Suto and M. Tatsuka, LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane, Mol Carcinog 39 (2004), 206-220. (Pubitemid 38452241)
29. C.M. Perou, T. Sorlie, M.B. Eisen, R.M. van de, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lonning, A.L. Borresen-Dale, P.O. Brown and D. Botstein, Molecular portraits of human breast tumours, Nature 406 (2000), 747-752.
30. M. Rahman, S.R. Davis, J.G. Pumphrey, J. Bao, M.M. Nau, P.S. Meltzer, and S. Lipkowitz, TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype, Breast Cancer Res Treat 113 (2009), 217-230.
31. P. Scherle, T. Behrens and L.M. Staudt, Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes, Proc Natl Acad Sci U S A 90 (1993), 7568-7572. (Pubitemid 23249991)
32. A. Schnelzer, D. Prechtel, U. Knaus, K. Dehne, M. Gerhard, H. Graeff, N. Harbeck, M. Schmitt and E. Lengyel, Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b, Oncogene 19 (2000), 3013-3020. (Pubitemid 30389092)
33. D. Schunke, P. Span, H. Ronneburg, A. Dittmer, M. Vetter, H.J. Holzhausen, E. Kantelhardt, S. Krenkel, V. Muller, F.C. Sweep, C. Thomssen, and J. Dittmer, Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells, Cancer Res 67 (2007), 10694-10702. (Pubitemid 350145895)
34. C.L. Sommers, S.W. Byers, E.W. Thompson, J.A. Torri and E.P.Gelmann, Differentiation state and invasiveness of human breast cancer cell lines, Breast Cancer Res Treat 31 (1994), 325-335. (Pubitemid 24323473)
35. D. Sun, D. Xu and B. Zhang, Rac signaling in tumorigenesis and as target for anticancer drug development, Drug Resistance Updates 9 (2006), 274-287. (Pubitemid 46357635)
36. L.J. t Veer and D. De Jong, The microarray way to tailored cancer treatment, Nat Med 8 (2002), 13-14.
37. J. Tapper, E. Kettunen, W. El Rifai, M. Seppala, L.C. Andersson and S. Knuutila, Changes in gene expression during progression of ovarian carcinoma, Cancer Genet Cytogenet 128 (2001), 1-6. (Pubitemid 32655473)
38. D. Theodorescu, L.M. Sapinoso, M.R. Conaway, G. Oxford, G.M. Hampton, and H.F. Frierson, Jr., Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer, Clin Cancer Res 10 (2004), 3800-3806. (Pubitemid 38697615)
39. B. Thiede, F. Siejak, C. Dimmler and T. Rudel, Prediction of translocation and cleavage of heterogeneous ribonuclear proteins and Rho guanine nucleotide dissociation inhibitor 2 during apoptosis by subcellular proteome analysis, Proteomics 2 (2002), 996-1006.
40. E.W. Thompson, S. Paik, N. Brunner, C.L. Sommers, G. Zugmaier, R. Clarke, T.B. Shima, J. Torri, S. Donahue, M.E. Lippman et al., Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines, J Cell Physiol 150 (1992), 534-44.
41. M.A. Thorat, Gene-signature-based prognostic tools in breast cancer: not yet, Lancet 369 (2007), 1428. (Pubitemid 46646953)
42. B. Zhang, Rho GDP dissociation inhibitors as potential targets for anticancer treatment, Drug Resist Updat 9 (2006), 134-141. (Pubitemid 44279520)
43. B. Zhang, Y. Zhang, M.C. Dagher and E. Shacter, Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis, Cancer Res 65 (2005), 6054-6062. (Pubitemid 40994389)
44. Y. Zhang, L.A. Rivera Rosado, S.Y. Moon and B. Zhang, Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling, J Biol Chem 284 (2009), 12956-12965.
45. Y. Zhang and B. Zhang, D4-GDI, a RhoGTPase regulator, promotes breast cancer cell invasiveness, Cancer Res 66 (2006), 5592-5598. (Pubitemid 43927109)
46. Y. Zhang and B. Zhang, TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5, Mol Cancer Res 6 (2008), 1861-1871.